For Research Use Only

SKI II

www.ptgcn.com

Catalog Number: CM06514

产品信息

Catalog Number:
CM06514

CAS号:
312636-16-1

分子式:
$C_{15}H_{11}ClN_2OS$

主要靶点:
Apoptosis|S1P Receptor|Wnt/beta-catenin

主要通路:
干细胞|细胞骨架|G 蛋白偶联受体|凋亡

分子量:
302.78

溶解度:
DMSO:40 mg/mL (132.11 mM)



靶点活性

SPHK:0.5 μM

体外活性

SKI II（50 mg/kg,i.p.）通过抑制小鼠内源性1-磷酸鞘氨醇生成,可改善抗原诱导的支气管平滑肌高反应性.在携带JC乳腺癌细胞的同源Balb/c小鼠实体瘤模型中, SKI II（50 mg/kg,i.p./p.o.）可显著降低肿瘤生长,与对照组相比,无明显的毒性或体重减轻.

体内活性

与降低S1P水平一致,SKI II可诱导T24细胞凋亡。在JC细胞中,SKI II可浓度依赖性降低S1P形成（IC50：12 μM）。在乳腺癌细胞系MDA-MB-231中,SKI II可明显抑制内源性SK活性。在人类癌细胞系,包括T-24,MCF-7,MCF-7/VP,NCI/ADR中,SKI II均有显著的抗增殖效果（IC50：4.6/1.2/0.9/1.3 μM）。此外,通过下调P-gp的表达,及通过下调SPHK1而上调凋亡,SKI II可逆转SGC7901/DDP对顺铂的耐药性。

细胞实验

T24, MCF-7, MCF-7/VP, and NCI/ADR cells are plated into 96-well tissue culture plates at ~15% confluency. After 24 hours, cells are treated with various concentrations of inhibitors. After an additional 48 hours, cell survival is assayed using the sulforhodamine B assay.(Only for Reference)

储存

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.